BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (APPROVED BY HEALTH CANADA FOR IBD INDICATIONS)

Entyvio®/Takeda/OnePath® (2015)

APPROVED CLINICAL INDICATIONS

(may vary within provinces – refer to local patient support program)

Crohn’s disease
Ulcerative colitis

CLASS

Monoclonal antibody integrin receptor blocker

ACTION

Blocks integrin α4β7 protein that is found on the surface of white blood cells, thereby reducing intestinal inflammation. Inflammation elsewhere in the body is unaffected.